Literature DB >> 16308213

Aetiology of community-acquired pneumonia: serological results of a paediatric survey.

Massimiliano Don1, Lolita Fasoli, Mika Paldanius, Raija Vainionpää, Marjaana Kleemola, Riitta Räty, Maija Leinonen, Matti Korppi, Alfred Tenore, Mario Canciani.   

Abstract

Serological methods are routinely used in the diagnosis of viral and atypical bacterial respiratory infections. Recently, they have also been applied to typical bacteria, such as Streptococcus pneumoniae. The aim of this study was to determine the aetiology of paediatric community-acquired pneumonia (CAP) in both ambulatory and hospitalized patients, by using antibody assays. During a 15-month prospective surveillance, paired sera were studied for antibodies to 14 microbes in 101 children with symptoms of acute infection and infiltrates compatible with pneumonia on chest radiographs. A potential causative agent was detected in 66 (65%) patients. Evidence of bacterial, viral and mixed viral-bacterial infection was demonstrated in 44%, 42% and 20% of the CAP cases, respectively. The most commonly found agents included Mycoplasma pneumoniae (27%), Pneumococcus (18%) and respiratory syncytial virus (17%). Human metapneumovirus (hMPV) was detected in 5 (5%) children. Pneumococcal infections were evenly distributed among the age groups studied. Our results confirm the role of S. pneumoniae in paediatric CAP at all ages, those of M. pneumoniae at >2 y of age and emphasize the emerging role of hMPV. The high proportion of mixed viral-bacterial infections highlights the need to treat all children with CAP with antibiotics.

Entities:  

Mesh:

Year:  2005        PMID: 16308213     DOI: 10.1080/00365540500262435

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  31 in total

1.  How to diagnose Mycoplasma pneumoniae etiology in a child with pneumonia?

Authors:  Matti Korppi
Journal:  Eur J Pediatr       Date:  2011-07-20       Impact factor: 3.183

2.  Pediatric community-acquired pneumonia in the ambulatory setting.

Authors:  Massimiliano Don; Francesca Valent
Journal:  Eur J Pediatr       Date:  2009-12-09       Impact factor: 3.183

Review 3.  The current status of community-acquired pneumonia management and prevention in children under 5 years of age in India: a review.

Authors:  Krishna Kumar Yadav; Shally Awasthi
Journal:  Ther Adv Infect Dis       Date:  2016-07-04

Review 4.  The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001-2015: A systematic review.

Authors:  Guijun Ning; Xuxia Wang; Dan Wu; Zundong Yin; Yixing Li; Huaqing Wang; Weizhong Yang
Journal:  Hum Vaccin Immunother       Date:  2017-09-18       Impact factor: 3.452

Review 5.  Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis.

Authors:  Christian Marchello; Ariella Perry Dale; Thuy Nhu Thai; Duk Soo Han; Mark H Ebell
Journal:  Ann Fam Med       Date:  2016-11       Impact factor: 5.166

6.  Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?

Authors:  Dilshad Ahmad Khan; Aisha Rahman; Farooq Ahmad Khan
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

7.  Prediction of delayed recovery from pediatric community-acquired pneumonia.

Authors:  Massimiliano Don; Francesca Valent; Mario Canciani; Matti Korppi
Journal:  Ital J Pediatr       Date:  2010-07-29       Impact factor: 2.638

8.  Hyponatremia in pediatric community-acquired pneumonia.

Authors:  Massimiliano Don; Giuliana Valerio; Matti Korppi; Mario Canciani
Journal:  Pediatr Nephrol       Date:  2008-07-08       Impact factor: 3.714

Review 9.  Pneumococcal serology in children's respiratory infections.

Authors:  M Korppi; M Leinonen; O Ruuskanen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-18       Impact factor: 3.267

10.  Respiratory syncytial virus infection in hospitalized children older than 2 years with community-acquired pneumonia.

Authors:  M Almasri; A Papa; E Souliou; K Haidopoulou; M Eboriadou
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.